ANTX AN2 THERAPEUTICS INC

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

Details of the event are as follows:

Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual)

  • Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Wednesday, February 12, 2025 at 3:20pm ET.

A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at . An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at .

EN
29/01/2025

Underlying

ANTXAN2 THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AN2 THERAPEUTICS INC

 PRESS RELEASE
Free
ANTX AN2 THERAPEUTIC...

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conf...

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference. Details of the event are as follows: Leerink Partners Global Healthcare Conference Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Wednesday, March 12, 2025 at 2:20 pm ET, and members of mana...

March 3, 2025 1 EN
 PRESS RELEASE
Free
ANTX AN2 THERAPEUTIC...

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment R...

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its submission of an amended statistical analysis plan to the FDA selecting the Quality of Life – Bronchiectasis (QOL-B) respiratory domain patient reported outcome (PRO) instrument as the primary efficacy endpoint for the Phase 3 part of the EBO-301 trial. The Company will evaluate whether the Phase 3 data supports the Phase 2 findings, where potential clinical...

February 24, 2025 1 EN
 PRESS RELEASE
Free
ANTX AN2 THERAPEUTIC...

AN2 Therapeutics to Participate at Upcoming Investor Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: TD Cowen 45th Annual Health Care Conference Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monday, March 3, 2025 at 2:30 pm ET, and members of management will be available for 1X1 meetings. ...

February 20, 2025 1 EN
 PRESS RELEASE
Free
ANTX AN2 THERAPEUTIC...

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Details of the event are as follows: Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Wednesday, February 12...

January 29, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
PBF PBF Energy Inc...
MYE Myers Industrie... ... (+15)

InsiderInsights.com Daily Ratings Report: December 10, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

PBF PBF ENERGY INC. CLASS A
MYE MYERS INDUSTRIES INC.
MTDR MATADOR RESOURCES COMPANY
ENTA ENANTA PHARMACEUTICALS INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
MEDP MEDPACE HOLDINGS INC.
PETS PETMED EXPRESS INC.
ETNB 89BIO
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
NOTV INOTIV
AHNR INC.
AUID ATHENA SILVER CORP
ANTX IPSIDY INC.
AVDL AN2 THERAPEUTICS INC
AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
12/11/24 December 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch